BASE: Aiming to test a simple, objective way to gauge bronchiectasis severity and predict flare-ups

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational cohort study enrolling adults with non-cystic fibrosis bronchiectasis to develop and validate the BASE framework. BASE uses objective baseline measurements from functional tests, imaging, oxygenation, and inflammatory markers to classify current severity and forecast future exacerbations over a 12-month period. The study design emphasizes baseline, non-interventional assessment with a structured scoring architecture and governance for development and validation. Data collection will occur at baseline with follow-up to identify bronchiectasis exacerbations and outcomes. Details on variable definitions and analytical rules are stored in restricted-access resources.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients aged 18 years or older.
* Diagnosis of non-cystic fibrosis bronchiectasis (NCFB) based on clinical assessment and high-resolution computed tomography (HRCT).
* Clinically stable or routinely assessed patients with non-cystic fibrosis bronchiectasis (NCFB) eligible for baseline severity and risk assessment.
* Patients attending outpatient clinic, inpatient ward, or respiratory follow-up services at Assiut University Hospitals during the study enrollment period.
* Patients suitable for prospective baseline assessment using the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework.
* Ability to undergo routine clinical, functional, radiological, oxygenation, and inflammatory assessment according to the study protocol.
* Ability to complete planned 12-month follow-up for bronchiectasis exacerbation and outcome assessment.
* Written informed consent obtained from the patient or legal representative.

Exclusion Criteria:

* Cystic fibrosis-related bronchiectasis.
* Traction bronchiectasis due to advanced fibrotic interstitial lung disease as the dominant respiratory diagnosis.
* Active pulmonary tuberculosis at enrollment.
* Active nontuberculous mycobacterial pulmonary disease requiring specific treatment at enrollment.
* Active malignancy or terminal non-respiratory illness expected to prevent 12-month follow-up.
* Acute life-threatening illness preventing safe enrollment or baseline assessment.
* Recent major thoracic surgery or acute thoracic trauma interfering with baseline respiratory assessment.
* Inability to complete the required baseline or Bronchiectasis Assessment of Severity and Exacerbations (BASE) assessment according to the study protocol.
* Inability or unwillingness to complete planned 12-month follow-up.
* Refusal to participate.

Where it's running

• Assiut university-Faculty of Medicine
  Asyut, Asyut Egypt, Egypt Recruiting

Study contacts

• Principal investigator: Ahmad M Shaddad, MD — Assiut University
• Study coordinator: Ahmad M Shaddad, MD
• Email: shaddad_ahmad@aun.edu.eg
• Phone: +201111171930

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Azithromycin added to usual care to see if it lowers bronchiectasis flare-ups

  This trial tests whether taking azithromycin daily for a year reduces bronchiectasis-related flare-ups in adults with non-cystic fibrosis bronchiectasis.

  Recruiting Phase 4 Assiut University · Asyut · NCT07608328

• Bronchiectasis Phenotype Identification Model for Adults

  This study tests a baseline classifier to categorize adults with non-cystic fibrosis bronchiectasis into phenotype groups using data collected over time.

  Recruiting Assiut University · Asyut, Assiut Egypt · NCT07599969

• Using hypertonic saline to improve mucus clearance in bronchiectasis

  This study is testing if a special salt solution delivered through a nebulizer can help adults with bronchiectasis clear mucus from their lungs better.

  Recruiting Phase 4 University of North Carolina, Chapel Hill · Chapel Hill, North Carolina · NCT06242795

• Chronic Respiratory Disease Participant Engagement

  This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.

  Recruiting Richmond Pharmacology Limited · London · NCT07924462

• Bronchoscopic Amikacin for Acute Exacerbations in Bronchiectasis

  This study tests whether delivering amikacin directly into the lungs during bronchoscopy helps adults with acute bronchiectasis flare-ups.

  Recruiting First Affiliated Hospital of Ningbo University · Ningbo, Zhejiang · NCT07813299

• Galvokimig vs placebo for non-CF bronchiectasis in adults

  This study tests whether Galvokimig can delay the first pulmonary flare compared with placebo in adults with non-CF bronchiectasis.

  Recruiting at 7 sites Phase 2 UCB Pharma · Newport Beach, California and 6 other locations · NCT07720375

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.